^
    Back
    Association details:
    Biomarker:TP53 R175H
    Cancer:Prostate Cancer
    Drug:APR-548 (p53 reactivator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Prostate
    Title:

    TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment

    Published date:
    10/09/2023
    Excerpt:
    Treatment with APR-246 reversed the effects of TP53 mutations in vitro and inhibited 22Rv1 TP53 R175H tumor growth in vivo in a dosage-dependent manner.
    DOI:
    10.1002/pros.24629